Abstract:Abstract Background Serine hydroxymethyltransferase 2 (SHMT2) is a vital metabolic enzyme in one carbon metabolism catalyzing the conversion of serine to glycine, which has been reported to play a crucial role in the progression of tumors. However, its function in tongue squamous cell carcinoma (TSCC) remains unclear. Methods SHMT2 expression was analyzed using samples in online databases, and was assessed through immunohistochemistry staining of collected clinical specimens. The correlation between SHMT2 expression and the cell cycle was predicted through bioinformatic analysis, including weighted gene co-expression network analysis (WGCNA) and gene set enrichment analysis (GSEA). After transfection with siRNA, CCK8 assay, Edu staining, flow cytometry, trans-well assay, and wound healing experiments were performed to verify the functional role of SHMT2 in vitro. A stable cell line with SHMT2 silencing was established to detect the oncogenic function of SHMT2 in vivo. Results The expression of SHMT2 was up-regulated in TSCC tissues and cell lines compared with normal groups, and highly expressed SHMT2 significantly indicated a poorer clinical outcome for TSCC patients. Bioinformatic analysis found that high expression of SHMT2 was closely related with biologic process including cell cycle and cell cycle G1/S transition. Down regulating of SHMT2 significantly suppressed the proliferation, invasive and migrative ability of TSCC cells, and induced the prolongation of the G1 phase of the cell cycle in vitro. Furthermore, western blot showed that cell cycle-related regulators such as cyclin-dependent kinase 4 (CDK4) and cyclinD1 expression levels were decreased, while the expression levels of the cyclin-dependent kinase inhibitors p21 Cip1 and p27 Kip1 were increased after SHMT2 knockdown. Silencing SHMT2 in the HN6 cell line using short hairpin RNA also impeded tumor growth in vivo. Conclusions Overexpression of SHMT2 in TSCC indicated low survival rates, and was associated with aggressive behaviors of TSCC. It was also found to be involved in cell cycle regulation of TSCC cells. SHMT2 may serve as a novel prognostic indicator of TSCC.

Inhibition of Euchromatic Histone Lysine Methyltransferase 2 (EHMT2) Suppresses the Proliferation and Invasion of Cervical Cancer Cells.

Ezh2-Mediated Repression Of Gsk-3 Beta And Tp53 Promotes Wnt/Beta-Catenin Signaling-Dependent Cell Expansion In Cervical Carcinoma

EHMT2 Suppresses ARRB1 Transcription and Activates the Hedgehog Signaling to Promote Malignant Phenotype and Stem Cell Property in Oral Squamous Cell Carcinoma

Histone Methyltransferase KMT2B Promotes Metastasis and Angiogenesis of Cervical Cancer by Upregulating EGF Expression

DNA methylation of miR-138 regulates cell proliferation and EMT in cervical cancer by targeting EZH2

The polycomb group protein enhancer of zeste 2 is a novel therapeutic target for cervical cancer.

Enhancer of zeste homolog 2 blockade by RNA interference is implicated with inhibited proliferation, invasion and promoted apoptosis in endometrial carcinoma.

Euchromatic Histone Lysine Methyltransferase 1 Regulates Cancer Development in Human Gastric Cancer by Regulating E-cadherin

Effect of ECT2 Gene on Proliferation of Cervical Cancer Cells and Its Mechanism

Long Non-Coding RNA Cancer Susceptibility Candidate 2 Inhibits the Cell Proliferation, Invasion and Angiogenesis of Cervical Cancer Through the MAPK Pathway.

EZH2-mediated Repression of GSK-3β and TP53 Promotes Wnt/β-catenin Signaling-Dependent Cell Expansion in Cervical Carcinoma.

Increased expression of EHMT2 associated with H3K9me2 level contributes to the poor prognosis of gastric cancer.

Influence of inhibition of EZH2 gene expression by RNA interference on epithelial-mes-enchymal transition in endometrial carcinoma cells

Clinical Implications of the Influence of Ehm2 on the Aggressiveness of Breast Cancer Cells Through Regulation of Matrix Metalloproteinase-9 Expression.

Enhancer of zeste homolog 2 expression is associated with tumor cell proliferation and invasion in cervical cancer.

Silencing SHMT2 inhibits the progression of tongue squamous cell carcinoma through cell cycle regulation

Mecp2 Inhibits Proliferation And Migration Of Breast Cancer Via Suppression Of Epithelial-Mesenchymal Transition

TET1 inhibits the migration and invasion of cervical cancer cells by regulating autophagy

Targeting EZH2 Regulates Tumor Growth and Apoptosis Through Modulating Mitochondria Dependent Cell-Death Pathway in HNSCC

Ehm2 Transcript Variant 1 Inhibits Breast Cancer Progression and Increases E-cadherin Stability.

Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation.